March 16, 2023
5 min watch
Supply/Disclosures
Printed via:
Disclosures:
Nguyen studies consulting for Bayer, Blue Earth Diagnostics, Boston Clinical, Janssen Oncology and Myovant Sciences; and receiving analysis investment from Astellas Pharma, Bayer and Janssen.
On this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Most cancers Institute, discusses the FORMULA-509 trial he co-presented at ASCO Genitourinary Cancers Symposium.
The learn about tested sufferers with a emerging PSA after radical prostatectomy who had no less than one negative chance issue, and who gained salvage radiation and six months of a gonadotropin-releasing hormone agonist.
âWhat I feel we will say now could be for a affected person lately, the usage of the FORMULA-509 routine is an excessively horny selection to having to elongate the length of hormone remedy to 24 months,â Nguyen mentioned.
Reference:
- Nguyen P, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and six months of GnRH agonist without or with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Introduced at: ASCO Genitourinary Cancers Symposium; ; Feb. 16-18, 2023; San Francisco.